Pairing a long-acting amylin analog with semaglutide was supposed to be Novo Nordisk's answer to tirzepatide. The REDEFINE program shows a real, large effect — and a head-to-head trial showing it still isn't quite enough.
Amylin
-
CagriSema and the Amylin Comeback -
Petrelintide and the Amylin-Only Bet Zealand Pharma's petrelintide drops the GLP-1 component entirely and still produced 10.7% weight loss with placebo-like tolerability in its lead Phase 2 trial — a real test of whether amylin alone can compete with the incretin class, backed by a $5.3 billion Roche partnership.